TuHURA Biosciences, Inc.

NasdaqCM:HURA Stock Report

Market Cap: US$188.7m

TuHURA Biosciences Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jim Bianco

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage37.5%
CEO tenureno data
CEO ownership5.5%
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Bianco's remuneration changed compared to TuHURA Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$19m

Dec 31 2023US$1mUS$464k

-US$29m

Dec 31 2022US$800kUS$400k

-US$9m

Compensation vs Market: Jim's total compensation ($USD1.24M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

CEO

Jim Bianco (67 yo)

no data

Tenure

US$1,235,485

Compensation

Dr. James A. Bianco, also known as Jim, M.D., serves as CEO, President & Director of Tuhura Biosciences, Inc (formerly known as Morphogenesis, Inc). He served as Chief Development Officer at Prothex, Inc....

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 06:32
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TuHURA Biosciences, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group